Bea S, Ko HY, Bae JH, Cho YM, et al. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut 2024 Sep 6:gutjnl-2024-332687. doi: 10.1136/gutjnl-2024-332687.
PMID: 39242193